Hepatitis C Virus Infections in Patients with Hemophilia: Links, Risks and Management

Figures & data

Table 1 Treatment of Hepatitis C Virus Infection with DAAs in Patients with Inherited Bleeding Disorders

Total Patients (n)	HIV (%)	Genotypes (%)	Regimens	Overall SVR Rate (%)	SVR Rate in HIV (%)	Reference
14	0	1a:71, 1b:29	SOF/LDV/RBV 12 weeks	SVR12: 100	N/A	Stedman 2015^Citation56
2	100	1a:100	SOF/DCV 24 weeks	SVR24: 100	SVR24: 100	Ackens 2016^Citation63
99	19	1:1, 1a:67, 1b:31, 4:1	SOF/LDV 12 weeks	SVR12: 99	SVR12: 100	Walsh 2017^Citation57
5	0	1a:100	SOF/LDV 24 weeks	SVR12: 100	N/A
10	40	2:100	SOF/RBV 12 weeks	SVR12: 100	SVR12: 100
6	50	3:100	SOF/RBV 24 weeks	SVR12: 83	SVR12: 100
43	75	1a:58, 1b:28, 4:11.5, 1a/2b:2.5	SOF/LDV 12 weeks	SVR12: 95	SVR12: 95	Nagao 2017^Citation66
107	5.6	1a:44, 1b:43, 4:11, 1-other:2	EBR/GZR 12 weeks	SVR12: 94.5	83	Hezode 2017^Citation58
30	Unknown	1a:17, 1b:70, 4:13	SOF/LDV, SOF/RBV 12 weeks, DCV/ASV 24 weeks	SVR12: 93	Unknown	Lee 2017^Citation59
27	100	1:7, 1a:15, 1b:59, 2a:4, 3a:11, 4a:4	SOF/LDV, SOF/RBV, SOF/DCV 12 weeks	SVR12: 100	SVR12: 100	Uemura 2017^Citation60
18	0	1:11, 1a:11, 1b:78	Various DAA regimens	SVR12: 94	N/A	Wiegand 2017^Citation64
7	0	1b:71, 3:29	SOF/DCV 12 or 24 weeks	SVR12: 100	N/A	Mehta 2017^Citation65
43	46	1a:58, 1b:28, 4:12, 1a/2b:2	SOF/LDV 12 weeks	SVR12: 95	SVR12:95	Nagao 2017^Citation66
3	10.8^b	1: 55, 2:8, 3:5, unknown: 31^b	DAC/SOF or SOF/simeprivir	SVR12: 100	Unknown	Giouleme 2018^Citation67
26^a	Unknown	1:70%, 2:8%, 3:19%^b	Various DAA regimens	SVR: 88	Unknown	Maticic 2018^Citation68
12	100	1b:75, 2:17, 3:8	Various DAA regimens	SVR24: 100	SVR24: 100	Xiao 2019^Citation61
85	2.8^b	1:1, 1a:11, 1b:67, 2:6, 3:9, 4:3, 5:2^b	Various DAA regimens	SVR: 91.6	Unknown	Fransen 2019^Citation69
16	Unknown	1a:38, 1b:44, 2:6, 3:6, unknown: 6	Various DAA regimens	SVR12: 100	Unknown	Pereira Guedes 2021^Citation10
147	4.1	1: 68.1, 2: 1.4, 3: 20.8, 4: 2.8, mix: 6.9	Various SOF-based DAA regimens	SVR12: 100	SVR12: 100	Sharafi 2021^Citation70
9	6.25^b	1: 50, 2: 15, 3: 35, 1a/1b:4^b	Unspecified	SVR12: 100	Unknown	Ružić 2021^Citation71

Notes: ^a26 DAA regimens offered-unspecified number of patients who received DAA treatment. ^bHIV co-infection and HCV genotyping data were reported for total cases, not patients who received DAAs.

Abbreviations: ASV, asunaprevir; DAA, direct-acting antiviral; DCV, Daclatasvir; EBR, Elbasvir; GZR, Grazoprevir; HIV, human immunodeficiency virus; LDV, Ledipasvir; RBV, Ribavirin; SOF, Sofosbuvir; SVR, sustained virological response.

Stedman CAM, Hyland RH, Ding X, Pang PS, McHutchison JG, Gane EJ. Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection. Haemophilia. 2016;22(2):214–217. doi:10.1111/hae.12791

 PubMed Web of Science ®Google Scholar

Ackens R, Posthouwer D. Treatment of chronic hepatitis C with direct acting antiviral agents in patients with haemophilia, end-stage liver disease and coinfected with HIV. Haemophilia. 2016;22(3):e223–e225. doi:10.1111/hae.12899

 PubMed Web of Science ®Google Scholar

Walsh CE, Workowski K, Terrault NA, et al. Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders. Haemophilia. 2017;23(2):198–206. doi:10.1111/hae.13178

 PubMed Web of Science ®Google Scholar

Nagao A, Hanabusa H. Brief report: the impact of ledipasvir/sofosbuvir on HIV-positive and HIV-negative Japanese hemophilia patients with 1, 4, and Mixed-Genotype HCV. J Acquir Immune Defic Syndr. 2017;74(4):418–422. doi:10.1097/QAI.0000000000001271

 PubMed Web of Science ®Google Scholar

Hézode C, Colombo M, Bourlière M, et al. Elbasvir/grazoprevir for patients with hepatitis C virus infection and inherited blood disorders: a phase III Study. Hepatology. 2017;66(3):736–745. doi:10.1002/hep.29139

 PubMed Web of Science ®Google Scholar

Lee HW, Yoo KY, Won JW, Kim HJ. Direct acting antiviral agents in Korean patients with chronic hepatitis C and hemophilia who are treatment-naïve or treatment-experienced. Gut Liver. 2017;11(5):721–727. doi:10.5009/gnl17209

 PubMed Web of Science ®Google Scholar

Uemura H, Tsukada K, Mizushima D, et al. Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders. PLoS One. 2017;12(10):e0186255. doi:10.1371/journal.pone.0186255

 PubMed Web of Science ®Google Scholar

Wiegand J, Schiefke I, Stein K, Berg T, Kullig U, Ende K. Interferon-free treatment of chronic hepatitis C virus infection in patients with inherited bleeding disorders. Hamostaseologie. 2017;37(2):127–130. doi:10.5482/HAMO-16-05-0014

 PubMed Web of Science ®Google Scholar

Mehta R, Kabrawala M, Nandwani S, et al. Daclatasvir-Sofosbuvir for treatment of hepatitis C virus in patients with inherited bleeding disorders. Indian J Gastroenterol. 2017;36(4):332–333. doi:10.1007/s12664-017-0777-x

 PubMed Web of Science ®Google Scholar

Giouleme O, Paschos P, Katsoula A, Panteliadou K, Vakalopoulou S, Garipidou V. Hepatitis C infection in a Greek population with inherited bleeding disorders. Haemophilia. 2018;24(2):e74–e76. doi:10.1111/hae.13427

 PubMed Web of Science ®Google Scholar

Maticic M, Lekše A, Kozinc M, et al. Micro-elimination of hepatitis C among patients with congenital bleeding disorders in Slovenia. J Hepatol. 2018;68:S193–S194. doi:10.1016/S0168-8278(18

 Web of Science ®Google Scholar

Xiao H, Chen J, Wang J, Li J, Yang F, Lu H. Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection. Medicine. 2019;98(30):e16524. doi:10.1097/MD.0000000000016524

 PubMed Web of Science ®Google Scholar

Fransen L, D’hondt P, Bielen R, et al. Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: a single‐centre experience. Haemophilia. 2019;25(6):1028–1034. doi:10.1111/hae.13829

 PubMed Web of Science ®Google Scholar

Pereira Guedes T, Garrido M, Kuttner Magalhães R, et al. Long-term follow-up of a Portuguese single-centre cohort of persons with haemophilia and hepatitis C virus infection. PJG. 2021;28(2):79–86. doi:10.1159/000510023

 Web of Science ®Google Scholar

Sharafi H, Behnava B, Azizi-saraji A, et al. Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders. Virol J. 2021;18(1):199. doi:10.1186/s12985-021-01659-0

 PubMed Web of Science ®Google Scholar

Ružić M, Rajić N, Fabri M, et al. Implementation of microelimination strategy in eradication of chronic hepatitis C infection in patients with hemophilia in the Northern region of Serbia: is eradication possible? Mediterr J Hematol Infect Dis. 2021;13(1):e2021058. doi:10.4084/MJHID.2021.058

 PubMed Web of Science ®Google Scholar